# A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Source: https://onco.cc/trials/nct06005974/  
OnCo record `nct06005974` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of REC-4881 run by Recursion Pharmaceuticals Inc., terminated.

## Summary

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation is a phase 2 interventional study registered as NCT06005974 by Recursion Pharmaceuticals Inc., with 18 participants enrolled, started 2024-01-15. Conditions recorded: AXIN1 Gene Mutation, APC Gene Mutation and Solid Tumor. Interventions recorded: REC-4881.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06005974
- Phase: 2
- Setting: A Phase 2, Open Label Study of REC-4881 in Participants With Unresectable Locally Advanced or Metastatic Cancer With AXIN1 or APC Mutation
- Sponsor: Recursion Pharmaceuticals Inc.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT06005974: https://clinicaltrials.gov/study/NCT06005974

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [REC-4881](https://onco.cc/drugs/rec-4881/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)

---
JSON: https://onco.cc/api/v1/entities/nct06005974.json